Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 15/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 13/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 11/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114772 | 0.93 | CTSS (0.44) | CHRM1CHRM2CHRM4S1PR2DGAT2 | |
| SCHEMBL2113188 | 0.88 | CHRM1 (0.46) | CHRM1CHRM2CHRM4NAMPTCTSS | |
| SCHEMBL2112400 | 0.87 | PDK2 (0.48) | CHRM1CHRM2CHRM4S1PR2CTSS | |
| SCHEMBL2710775 | 0.86 | CHRM1 (0.47) | CHRM1CHRM2CHRM4NAMPTCTSS | |
| SCHEMBL2610205 | 0.85 | CHRM1 (0.49) | CHRM1CHRM2CHRM4NAMPTCTSS | |
| SCHEMBL2114310 | 0.79 | CTSS (0.53) | S1PR2NAMPTDGAT2CTSS | |
| SCHEMBL2114521 | 0.79 | CTSS (0.44) | CHRM1CHRM2CHRM4CTSS | |
| SCHEMBL1583532 | 0.78 | P2RX7 (0.51) | ENPP2 | |
| SCHEMBL2610206 | 0.76 | CTSS (0.47) | CHRM1CHRM2CHRM4CTSS | |
| SCHEMBL2113051 | 0.75 | CHRM1 (0.49) | CHRM1CHRM2CHRM4NAMPTCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630141-A1 | CATHEPSIN S INHIBITOR COMPOUNDS | Eli Lilly and Company (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8227468-B2 | Cathepsin S inhibitor compounds | ELI LILLY AND COMPANY (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227468-B2 | Cathepsin S inhibitor compounds | ELI LILLY AND COMPANY (US) | 2012-07-24 | — | — | US | disclosed |
| WO-2012054315-A1 | CATHEPSIN S INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012054315-A1 | CATHEPSIN S INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | ELI LILLY AND COMPANY (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | ELI LILLY AND COMPANY (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | CTSS, CTSZ, CTSV | CHRM1 4241/4885CHRM2 4275/4885CHRM4 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.